---
schema_version: "secwatch.filing_event.v1"
accession: "0001739104-25-000052"
form_type: "8-K"
ticker: "ELAN"
cik: "0001739104"
company_name: "Elanco Animal Health Inc"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:57:08.736786+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elanco Q2 rev +5% to $1.24B, raises FY2025 outlook; net leverage target improved

## Summary
- Q2 revenue $1,241M (+5% reported, +8% organic CC); adjusted EPS $0.26 vs $0.30 prior year.
- FY2025 revenue guidance raised to $4,570-4,620M; adjusted EPS raised to $0.85-0.91.
- Full-year innovation revenue target increased by $60M to $720-800M; Credelio Quattro and Experior drive growth.
- Net leverage ratio improved to 4.0x at Q2 end; year-end target tightened to 3.8x-4.1x.
- Robert VanHimbergen appointed EVP and CFO effective July 7, 2025.

## SEC filing metadata
- accession: 0001739104-25-000052
- form_type: 8-K
- ticker: ELAN
- cik: 0001739104
- company_name: Elanco Animal Health Inc
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739104/000173910425000052/0001739104-25-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739104/000173910425000052/elan-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739104-25-000052
- JSON: https://secwatch.observer/filing/0001739104-25-000052.json
- Plain text: https://secwatch.observer/filing/0001739104-25-000052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.